Aficamten Approval Reshapes CMC Demands for Cardiac Myosin Inhibitors

Cytokinetics secured FDA approval for MYQORZO (aficamten) on December 19, 2025, positioning the company inside a drug class where chemistry, manufacturing, and controls (CMC) complexity is rapidly becoming a competitive differentiator. As a second cardiac myosin inhibitor to reach the U.S. market alongside Bristol Myers Squibb's mavacamten, aficamten's approval signals that manufacturers in this space must now manage dose-titration-sensitive supply chains, tight LVEF monitoring thresholds, and the process validation demands that accompany a once-daily oral tablet requiring individualized dosing up to 20 mg.

The FDA based its approval on SEQUOIA-HCM (NCT05186818), a randomized, double-blind, placebo-controlled trial enrolling 282 adults with symptomatic NYHA class II and III obstructive hypertrophic cardiomyopathy (oHCM). Patients required a left ventricular ejection fraction (LVEF) of 60% or greater and specific resting and post-Valsalva peak left ventricular outflow tract gradients at screening. Dosing began at 5 mg once daily, with titration at Weeks 2, 4, and 6 in 5 mg increments, contingent on Valsalva LVOT-G and LVEF parameters. The primary endpoint was change from baseline in peak oxygen uptake by cardiopulmonary exercise testing at Week 24. The trial ran across 82 sites in 14 countries, with 94 U.S. patients and 188 enrolled internationally.

For QA directors and plant heads, the titration architecture of MYQORZO carries direct manufacturing implications. A regimen requiring individualized dose escalation across four strength levels demands robust content uniformity data, validated packaging configurations, and labeling controls that align with 21 CFR Part 211 requirements for oral solid dosage forms. The LVEF-gated titration criteria also suggest that post-market pharmacovigilance and risk management will be closely tied to prescriber compliance with the dosing algorithm, placing additional weight on the prescribing information as a GMP-adjacent control document.

The international trial footprint, spanning Czech Republic, Germany, France, the United Kingdom, Israel, and nine other countries, introduces ICH Q10 pharmaceutical quality system considerations for sites contributing to the dataset. Regulatory affairs leads preparing for potential label updates or post-approval commitments should note that the Snapshot data reflects only the original approval population and does not capture any subsequent indication expansions.

Source: FDA Drug Trials Snapshots: MYQORZO, published April 28, 2026, based on original approval dated December 19, 2025. Full prescribing information and approved conditions of use are available via the FDA MYQORZO label.